阿尔茨海默病：更新的多靶点治疗药物正在临床进行中。
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress.
机构信息
State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, China; School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, 570228, China.
College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, 473061, China.
出版信息
Eur J Med Chem. 2022 Aug 5;238:114464. doi: 10.1016/j.ejmech.2022.114464. Epub 2022 May 20.
Alzheimer's disease is a chronic and progressive brain neurodegenerative disease affecting over 30 million people globally. Currently, no effective treatment is available due to multiple factors involved in the progression of AD. Given that the numerous AD-related targets in the disease network, the multi-target-directed ligands (MTDLs) strategy are considered as the promising strategy to treat AD. Herein, the multi-target compounds with/without ChEs are in clinical and in progress are reviewed. To further characterize the drug-likeness, and ADME properties are calculated using the Qikprop. This review will provide highlights for the treatment of AD.
阿尔茨海默病是一种慢性进行性脑神经退行性疾病，影响着全球超过 3000 万人。目前，由于 AD 进展涉及多种因素，尚无有效的治疗方法。鉴于疾病网络中存在大量的 AD 相关靶点，多靶点定向配体（MTDLs）策略被认为是治疗 AD 的有前途的策略。本文综述了具有/不具有 ChE 的多靶化合物在临床和进展中的情况。为了进一步表征药物样性质和 ADME 特性，使用 Qikprop 进行了计算。本文综述将为 AD 的治疗提供重点。
Zotero 插件